Be aware that the benefits of biological drugs in multiple sclerosis may be offset by their capacity to cause immunological complications
- 4 Downloads
Biological immunotherapies for multiple sclerosis (MS) include recombinant proteins (preparations of interferon-β) and monoclonal antibodies (e.g. natalizumab, alemtuzumab, ocrelizumab and off-label rituximab). They have shown unprecedented efficacy in the treatment of MS; however, they are all immunogenic and have been associated with immunological complications, such as neutralizing immunogenicity, secondary immunodeficiency and secondary autoimmunity.
Compliance with ethical standards
Conflict of interest
The article was adapted from Drug Safety 2019; 42(8):941–56 by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.
The preparation of this review was not supported by any external funding.
- 25.Ocrevus® (ocrelizumab): US prescribing information. South San Francisco: Genentech Inc; 2019.Google Scholar
- 27.Kadish R, Robertson D, Sweeney M. Fatal leukoencephalopathy in a patient with multiple sclerosis following treatment with ocrelizumab. Neurology. 2018;90(15 Suppl):5.353.Google Scholar